1. Introduction {#s0005}
===============

Mitochondrial aminoacyl tRNA synthetases (aaRSs) are essential for mitochondrial protein biosynthesis and oxidative phosphorylation \[[@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]\]. Nineteen nuclear genes encode the aaRSs, including prolyl-tRNA synthetase 2, or *PARS2*, which charges mitochondrial prolyl-tRNA with its cognate amino acid, proline.

Biallelic pathogenic *PARS2* variants are associated with early infantile epileptic encephalopathy (EIEE75, MIM 618437), a multi-system mitochondrial disorder. Clinical features previously observed in nine individuals with *PARS2* deficiency include microcephaly, hypotonia, seizures, intellectual disability, structural brain abnormalities, and other systemic findings including lactic acidemia. All patients generally have similar characteristics and symptoms, with most dying during the first 10 years of age \[[@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055]\] ([Table 1](#t0005){ref-type="table"}).Table 1Overview of different cases with PARS2-related mutations (our case and other previously published cases).Table 1Our CaseSofou et al. \[[@bb0050]\] (1st case report of PARS2 mutation)Pronicka et al. \[[@bb0045]\]Mizuguchi et al. \[[@bb0030]\]Ciara et al. \[[@bb0040]\]Yin et al. \[[@bb0035]\]Al Balushi et al. \[[@bb0055]\]SexMaleMaleMale2 sisters3 siblings (Two brothers and one sister)2 sistersFemaleFamily historyEldest brother ha same phenotype.Not mentionedAffected siblings (no details given)2 affected sisters, no mention of any other family member3 affected siblings (2 brothers and 1 sister).2 affected sisters, no mention of any other family memberNot mentionedLongevityDied at 21 years, brother died at 5 yearsDied at the age of 16 yearsDied under 2 yearsBoth alive at the time of report publishing(9 and 3 years of age)Elder brother and sister died at 8.5 years; youngest brother alive at the time of report (6.5 years)Younger one died at 4 months; older one alive at the time of report (3 years)Alive at time of report publishing (3.3 years)  Clinical findingsDevelopmental delay+++++++Hypotonia++++++HypertoniaMicrocephaly++++++−Type of seizureInfantile spasms, generalized seizureIntractable epileptic encephalopathyGeneralized seizureGeneralized seizureGeneralized seizureGeneralized seizureInfantile spasmsCardiomyopathy++Not knownNot examined+NilNilOther organ involvementsFrequent episodes of respiratory infection, feeding difficultyVisual impairment, feeding difficultyNot knownNilFacial dysmorphism; visual impairment, hyperacusisFeeding difficultyCoagulation abnormalities  Diagnostic findingsMRI brainFrontal and anterior parietal atrophy with signal changes involving caudate, lentiform nuclei, and thalami bilaterallySupratentorial atrophy of the cerebral cortex, complete agenesis of the corpus callosum, and hypomyelination of the white matterDone; findings not knownDiffuse hypomyelination,Progressive volume loss of frontal lobes; widening of cortical sulci and frontal horns of lateral ventriclesHypomyelination with cortical atrophy, decreased frontal lobe volume.Cerebral atrophy, Bifrontal subdural hematoma.EEG findingsHigh amplitude and posteriorly accentuated spike activity hypsarrhythmiaBilateral synchronous spikes and polyspikes, mainly in posterior regions of hemispheres, with generally depressed background activityDone; findings not knownHypsarrhythmiaHypsarrhythmiaHypsarrhythmia, multifocal spikes, sharp waves with a symmetric background patternNot reportedLactate levelsNormal; high only on one occasionElevated (serum and CSF)Elevated (only mentioned that lactate excretion was elevated)Elevated lactate (serum and CSF); not tested in CSF of the second siblingCSF lactate level normal; plasma lactate level highElevated serum lactate levels; CSF levels were not testednormalMuscle/skin biopsyNegative (skin biopsy)Increased fiber caliber variation; no mitochondrial proliferation, and structurally abnormal mitochondriaDone; findings not knownNot doneNormal histological and histochemical picture and activities of respiratory chain complexes I--IV at the control range, except for citric synthase activity (increased at 281 nmol/min/mg)Not doneNot doneECHOInitially normal. Severe degree of heart failure; EV 20%Dilated cardiomyopathy, left ventricular hypertrophyDone; findings not knownNot doneDilated/hypertrophic cardiomyopathyNormalNormalGenotype (ES)Compound heterozygous variants: maternally-inherited c.283G \> A (p.Val95Ile) and paternally-inherited 1091C \> G (p.Pro364Arg)Compound heterozygous variants: c.1130dupC, (p.K378 fs\*1); 836C \> T, (p.S279L),. located in a conserved motif of unknown functionCompound heterozygous variants: c.1091C \> G (p.Pro364Arg); c.239 T \> C (p.Ile80Thr)Compound heterozygous variants in both siblings: c.283G4A (p.Val95Ile); c.607G4A (p.Glu203Lys)Compound heterozygous variants: c.239 T \> C, (p.Ile80Thr) c.1091C \> G, (p.Pro364Arg)Compound heterozygous variants c.283 G \> A (p.V95I) and c.604G \> C (p.R202G)Compound heterozygous variants c.1091C \> G (p.Pro364Arg) c.283G \> A (p.Val95Ile)TreatmentACTH, and other antiepileptics; low dose aspirin, lisinopril, digoxin, carvedilol; mitochondrial "cocktail"Antiepileptic drugs and other supportive treatment; did not receive mitochondrial "cocktail"Antiepileptic drugs and other supportive treatment; did not receive mitochondrial "cocktail"Antiepileptic drugs and other supportive treatment; did not receive mitochondrial "cocktail"Antiepileptic drugs and other supportive treatment; did not receive mitochondrial "cocktail"Antiepileptic drugs and other supportive treatment; did not receive mitochondrial "cocktail"Not reported

Herein, we report the case of an individual with heterozygous pathogenic *PARS2* variants diagnosed through exome sequencing. Unlike most previous cases, chronic lactic acidemia was not present, and cardiomyopathy did not occur until adulthood (19 years). He died of cardiac failure at 21 years of age. To our knowledge, this patient had the longest lifespan with this disorder.

2. Case presentation {#s0010}
====================

*Clinical Course.* This male patient presented initially at eight months with epilepsy, global delays, and recurrent respiratory infections. Electroencephalography (EEG) revealed high-amplitude, posteriorly accentuated spikes consistent with hypsarrhythmia. Initial seizures were intractable, despite antiepileptics, but were gradually controlled with adrenocorticotrophic hormone (ACTH). Biochemical analysis revealed a single serum lactate elevation during infancy (which was normal on follow-up evaluations), normal amino acid levels in plasma and cerebrospinal fluid, and normal urine organic acids. Peroxisomal studies yielded normal results. Brain MRI revealed frontal and anterior parietal atrophy with signal changes involving the caudate, lentiform nuclei, and bilateral thalami. Karyotype was normal and fluorescence *in situ* hybridization revealed negative results for Angelman syndrome. Initial ophthalmologic and audiologic examinations and mitochondrial enzyme assays in fibroblasts revealed normal findings. Because an older deceased sibling had a similar presentation, an unknown mitochondrial disorder was speculated and an antioxidant vitamin mixture including vitamins C, B1, B2, B3 (100 mg twice daily), and E (200 mg twice daily), Q10, lipoic acid, and levocarnitine (250 mg thrice daily) was prescribed. Other medications included levetiracetam to control seizures. Throughout childhood, his cardiovascular function was stable, presenting normal findings on echocardiography, and only several illnesses requiring hospitalizations for respiratory distress and occasionally increased seizure frequency. Surgeries included posterior spinal fusion for scoliosis and surgical release of bilateral knee contractures. He had global developmental delay throughout childhood, but no developmental regression.

At 19 years, the patient presented with viral illness and dehydration, and echocardiography showed mildly depressed cardiac function with left ventricular ejection fraction of 50%,; low-dose lisinopril was administered. Physical examination revealed normal height and weight, microcephaly (circumference below the second percentile), with flattened occiput, mildly dysmorphic facial features including synophrys, malar hypoplasia, and mild prognathism, chin crease, and diffuse hypotonia ([Fig. 1](#f0005){ref-type="fig"}). He was nonverbal but responded to simple commands, interacted with his family, and was independently ambulatory.Fig. 1The patient at age 15 years. Findings included: microcephaly with flattened occiput, mildly dysmorphic facial features with synophrys, malar hypoplasia, mild prognathism, and chin crease.Fig. 1

Two years later, echocardiography revealed severe cardiac failure with a left ventricular ejection fraction of 20%. Aspirin, digoxin, carvedilol, and lisinopril were prescribed at low doses. He was readmitted twice with respiratory distress and suspected viral illness and was then discharged to home hospice and died of cardiac failure at 21 years of age.

*Family History.* The patient\'s eldest brother presented at 4 months with infantile spasms, which progressed to seizures, nystagmus, and profound intellectual disability. Brain magnetic resonance imaging (MRI) revealed cerebral atrophy. At 5 years, he died from severe cardiomyopathy and lactic acidosis. An underlying mitochondrial disease was suspected. Muscle biopsy indicated variations in myofiber size, reduced activity of multiple respiratory chain enzymes, and normal electron microscopic findings. Cytochrome c oxidase activity ranged from 0.04 (control 0.52 ± 0.17 in the brain) to 0.64 (2.8 ± 0.52). Cytochrome c oxidase staining revealed equivocal results. Increased citrate synthase activity was consistent with mitochondrial proliferation. Autopsy revealed frontal cerebral cortex atrophy and normal cortical mitochondria. The patient had another healthy older brother.

*Molecular Findings.* Written consent was obtained from the family for trio-exome sequencing. The patient harbored compound heterozygous variants of uncertain significance: c.1091C \> G (p.P364R), inherited paternally, and c.283 G \> A (p.V95I), inherited maternally. This exact genotype has been reported recently by Al Balushi et al. \[[@bb0055]\]. Monoallelic P364R in *PARS2* was reported in four different individuals with congenital microcephaly, early infantile epileptic encephalopathy, dilated cardiomyopathy, and Leigh syndrome-like disease \[[@bb0040],[@bb0045]\]. *In silico* analyses predicted deleterious effects. V95I was previously reported in four individuals with early infantile epileptic encephalopathy and hypotonia \[[@bb0030],[@bb0035]\]. It has also been reported in the homozygous state by Maddirevula et al. \[[@bb0060]\]. The c.1091C \> G (p.P364R) allele has been found in 295 out of 281,922 alleles, whereas the c.283 G \> A (p.V95I) was found in 31 out of 282,762 alleles in the GnomAD database. However, neither were found in the homozygous state in GnomAD.

3. Discussion {#s0015}
=============

Herein, we report the oldest documented patient harboring biallelic *PARS2* pathogenic variants with cardiac function preserved until shortly before death, who had the longest lifespan in this condition reported thus far.

*PARS2* mutations are rare, previously reported in only nine patients ([Table 1](#t0005){ref-type="table"}). Our patient harbored one mutation (P364R) in common with the eldest of three affected siblings ([Table 1](#t0005){ref-type="table"}). The elder brother and sister both died at 8.5 years of age \[[@bb0040]\]. Two sisters harboring *PARS2* mutations \[[@bb0035]\] shared one pathogenic variant with our patient, c.283 G \> A (p.V95I) ([Table 1](#t0005){ref-type="table"}). The younger sister died at 4 months, while the elder sibling was 3 years at the time of publication. None of these patients were treated with antioxidants. All had elevated lactate levels, unlike our patient.

Though our patient periodically required hospitalization, he survived for two decades. Among supportive therapies, he received a regimen of antioxidant supplements targeting mitochondrial dysfunction since infancy. Furthermore, he had an affected older brother, who received no treatment and died during early childhood from cardiac failure.

Some treatment strategies for mitochondrial diseases involve bypassing mitochondrial functions, including natural substances directly involved in ATP production, such as creatine (when the ATP demand exceeds the mitochondrial supply, creatine releases phosphate to increase ATP production), carnitine (improves ATP efficiency by clearing the toxic byproducts of ATP synthesis and facilitating ATP production by importing fuel molecules in the mitochondria), and coenzyme Q10 (essential for mitochondrial respiration) \[[@bb0065]\].

Mitochondrial cytopathies are associated with reduced transduction of aerobic energy (decreased ATP synthesis), increased oxidative stress, apoptosis, and necrosis. Theoretically, combinations of specific nutraceuticals bypass deficiencies in mitochondrial respiration, potentially providing an alternate energy source \[[@bb0065],[@bb0070]\]. A previous randomized placebo-controlled trial involving patients with mitochondrial cytopathies reported that creatine monohydrate, alpha lipoic acid, and coenzyme q10 reduced lactate levels and oxidative stress (as indicated by its markers) \[[@bb0065]\].

While numerous factors could have contributed to significant differences in disease severity between our patient and his sibling, we hypothesize that antioxidant supplementation may have delayed the onset of cardiomyopathy and contributed to normal lactate levels. Further prospective studies with larger cohorts and well-defined clinical and laboratory markers are required to establish the beneficial roles of antioxidants and other vitamins in individuals with *PARS2-*associated disease.
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